Monitor upcoming data readouts in late 2026/early 2027 from ReSTART pivotal trial and REGAIN glioblastoma trial, which are key catalysts for FDA approval prospects. The Tolmar partnership provides non-dilutive funding and commercial pathway for prostate cancer.
Drug in focus
DRTS drug pipeline →Alpha DaRT
▲ Bullish Named in this press release- Impact
- Phase
- Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
- Time to market
- The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
- Next catalyst
- None dated
What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $14.27entry
- T+1 · 3mo ago −2.80%α −3.05% · $13.87
- T+5 · 3mo ago −0.07%α +0.33% · $14.26
- T+20 · 2mo ago 0.00%α +1.06% · $14.27
- T+60 · 13d ago −1.68%α −1.20% · $14.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical reported Q2 2026 financial results with a net loss of $68.8 million for the six months ended June 30, 2026, compared to $18.8 million in the same period of 2025, driven by higher R&D expenses and a $41.4 million financial expense from warrant remeasurement. The company highlighted multiple clinical milestones including 100% local disease control in glioblastoma, completion of enrollment in its pivotal cSCC trial, and a strategic collaboration with Tolmar for prostate cancer. Cash balance of $104.8 million provides runway for ongoing trials.
Key Financial Metrics
Key Facts
- Net loss for six months ended June 30, 2026 was $68.8 million ($0.76 per share) vs $18.8 million ($0.25 per share) in 2025
- Cash and equivalents, short-term deposits and restricted deposits of $104.8 million as of June 30, 2026
- Tolmar strategic collaboration includes $20M equity investment at 25% premium, $15M for manufacturing, and up to $161.5M in milestones
- REGAIN glioblastoma trial showed 100% local disease control and 67% complete response rate in first three patients
- ReSTART pivotal cSCC trial fully enrolled with 88 patients
- Head and neck cancer combination study with pembrolizumab showed 100% objective response rate and 18.2-month median overall survival
Financial Impact
Net loss increased by $50M year-over-year; cash burn rate elevated; $20M equity investment from Tolmar at premium
Risk Factors
- No revenue generating product; company is pre-commercial with significant operating losses
- Warrant liability remeasurement creates volatility in reported financial results
- Clinical trial results may not replicate in larger studies or lead to regulatory approval
- Dependence on successful commercialization of Alpha DaRT technology
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342184 |
Track record
25 reports on DRTS
9 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers